A new series of 2,4-thiazolidinediones endowed with potent aldose reductase inhibitory activity

Creative Commons License

Sever B., Altlntop M. D., Demir Y., Türkeş C., Özbaş K., Çiftçi G. A., ...Daha Fazla

Open Chemistry, cilt.19, sa.1, ss.347-357, 2021 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 19 Sayı: 1
  • Basım Tarihi: 2021
  • Doi Numarası: 10.1515/chem-2021-0032
  • Dergi Adı: Open Chemistry
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CAB Abstracts, Veterinary Science Database, Directory of Open Access Journals
  • Sayfa Sayıları: ss.347-357
  • Anahtar Kelimeler: aldose reductase, thiazolidinedione, cytotoxicity, molecular docking, IN-SILICO, CARBONIC-ANHYDRASE, DERIVATIVES, VITRO, ACETYLCHOLINESTERASE, COMPLICATIONS, INSIGHTS, TARGETS, DESIGN
  • Erzincan Binali Yıldırım Üniversitesi Adresli: Evet

Özet

© 2021 De Gruyter. All rights reserved.5-(2-Hydroxy-3-methylbenzylidene)thiazolidine-2,4-dione (3) was identified as the most potent AR inhibitor in this series, exerting uncompetitive inhibition with a Kivalue of 0.445 ± 0.013 μM. © 2021 Belgin Sever et al., published by De Gruyter 2021.In an effort to identify potent aldose reductase (AR) inhibitors, 5-(arylidene)thiazolidine-2,4-diones (1-8), which were prepared by the solvent-free reaction of 2,4-thiazolidinedione with aromatic aldehydes in the presence of urea, were examined for their in vitro AR inhibitory activities and cytotoxicity. 5-(2-Hydroxy-3-methylbenzylidene)thiazolidine-2,4-dione (3) was the most potent AR inhibitor in this series, exerting uncompetitive inhibition with a Ki value of 0.445 ± 0.013 μM. The IC50 value of compound 3 for L929 mouse fibroblast cells was determined as 8.9 ± 0.66 μM, pointing out its safety as an AR inhibitor. Molecular docking studies suggested that compound 3 exhibited good affinity to the binding site of AR (PDB ID: 4JIR). Based upon in silico absorption, distribution, metabolism, and excretion data, the compound is predicted to have favorable pharmacokinetic features. Taking into account the in silico and in vitro data, compound 3 stands out as a potential orally bioavailable AR inhibitor for the management of diabetic complications as well as nondiabetic diseases.